Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
35 hedge funds and large institutions have $83.7M invested in Astria Therapeutics in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
75% more funds holding
Funds holding: 20 → 35 (+15)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.07% less ownership
Funds ownership: 68.76% → 67.69% (-1.1%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
35% less capital invested
Capital invested by funds: $129M → $83.7M (-$45.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.28M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$862K |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$416K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$388K |
| 5 |
SIM
Spark Investment Management
New York
|
+$387K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.75M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.41M |
| 3 |
DM
Deerfield Management
New York
|
-$1.3M |
| 4 |
CC
Clearline Capital
New York
|
-$571K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$488K |
ATXS Hedge Fund Activity: Q3 2015 in Review
35 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2015, worth a combined $83.7M — down 35% from $129M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATXS positions and 5 closed out — a net gain of 15 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $1.28M. The largest seller was BVF Inc, exiting entirely with an estimated $2.75M sold.
- 35 institutional investors held Astria Therapeutics (ATXS) as of Q3 2015, up from 20 in Q2 2015.
- Funds reported $83.7M of Astria Therapeutics stock for Q3 2015, down 35% quarter-over-quarter.
- 20 funds opened new Astria Therapeutics positions in Q3 2015 and 5 closed out, a net change of +15 holders.
- The largest Astria Therapeutics buyer in Q3 2015 was BlackRock Fund Advisors, an estimated $1.28M added.
- The largest Astria Therapeutics seller in Q3 2015 was BVF Inc, an estimated $2.75M sold.
Based on aggregated 13F filings for Q3 2015.